CORS at ISPE 2022, Copenhagen
Christine E. Hallgreen and Helle Christiansen will present two posters at the 38th International Conference on Advancing Pharmacoepidemiology and Real-World Evidence for the Global Community. Additionally, Mathias Møllebæk was involved in a Symposium discussion. As in previous years, the conference is organized by the International Society for Pharmacoepidemiology (ISPE). It will be held from Aug 24 - 28, 2022, at Bella Center, Copenhagen, Denmark.
Session A: Friday, August 26, 8:00am - 6:00pm
Poster 5
Guidance for Pediatric Use in Prescription Information for Novel Medicinal Products in The EU and the US
Helle Christiansen, Marie L. De Bruin, Sven Frøkjær, and Christine E. Hallgreen
Presenting author: Helle Christiansen
Poster 259
Marketing authorisation pathways and clinical evidence supporting approval of orphan medicinal products in EU between January 2015 and October 2021
Ertogrul Corap, Mathias Møllebæk, Christine E. Hallgreen
Presenting author: Christine E. Hallgreen
This poster is the result of one of CORS Master student projects.
Session: Symposia & Workshops: Session 4
Updating the Public on COVID-19 Vaccine Safety - Considerations for Pharmacoepidemiologists
Sunday, August 28, 2022
10:30 AM – 12:00 PM CEST
Location: Congress Hall D5
Publication Number: 244
Background: The risks and benefits of COVID-19 vaccines have been at the center of public attention throughout the pandemic. Among other fields of expertise, pharmacoepidemiologists have been tasked with communicating about vaccines in a wide variety of outlets. While this has demonstrated the importance of pharmacoepidemiology for public policy and public health, it has also elucidated challenges with public communication about vaccines, such as engaging with policy-makers and experts from other fields, balancing trust, clarity, and transparency and managing the tension between advocating and informing policy.
This symposium raises these and other crucial issues with the aim of staking out future avenues for risk-benefit communication by pharmacoepidemiologists.
The symposium continues discussions at the 2021 ISPE symposium on Communicating COVID-19 Pharmacoepidemiological Research to Patients and aims to facilitate future work on public communication of vaccine and pharmacoepidemiology based on the latest experiences and evaluation of communications.
Objectives: Identify the most salient lessons learned about public communication of risks and benefits regarding messaging, selecting platforms, and other dissemination factors
Discuss motivating examples and opportunities to better communicate to address public concerns and public health needs
Discuss which methods and concepts can be adapted from other disciplines, e.g., social sciences and other health topics.
Discuss the role of ISPE in facilitating communication with patients and the public and engaging ISPE members in the next steps.
Description: This symposium offers five perspectives from different countries, stakeholders, and scientific disciplines on the practice and implications involved in communicating the results of pharmacoepidemiological studies to the public. The symposium will conclude with a moderated discussion between the audience and the panelists, focusing on how to build on the lessons learned and how ISPE can help advance public communication efforts.
- Introduction, Dr. Mathias Møllebæk (5 min)
- Updating the Public on COVID-19 Vaccines Safety, Dr. Priya Bahri (11 min)
- Visualizing the Benefit-Risk Balance of Vaccines, Is It Helpful?, Dr. Peter Mol (11 min)
- Rapid Message Testing and Countering Misinformation Using Social Media Simulations, Dr. Nabarun Dasgupta (11 min)
- Vaccine Communication In Australia, Dr. Barbara Mintzes (11 min)
- Vaccinations End Pandemics, Not Vaccines: Lessons from Communication Sciences, Dr. Mathias Møllebæk (11 min)
- Moderated panel session (30 min); What are the most salient lessons about communicating benefits and risks of vaccines? Dr. Anton Pottegård (moderator)
More info on the website "International Society for Pharmacoepidemiology".